This controversy has escalated by the findings that cancer patients who receive therapy with immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway, seem to have an increased risk of reactivating latent TB infection (2, 3). This evidence concerns the gene CD274 and cancer.